---
subject: Approval - FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
---

{{> header-secondary }}

<wrapper class="header header-primary">
	<container>

		<row class="collapse">
			<columns small="12" large="6" valign="middle">
				<img class="logo logo-ddc small-float-center" src="https://www.drugs.com/newsletters/src/logo-ddc.jpg" width="211" height="44" alt="Drugs.com">
			</columns>
			<columns small="12" large="6">
				<p class="small-text-center text-right" valign="middle">
					<span class="header-title">New Drug Approval</span><br>
					<span class="header-sub-title">PLACEHOLDER_DATE</span>
				</p>
			</columns>
		</row>
	</container>

</wrapper>

<container>
	<row>
		<columns small="12">
				
			<h2><a href="#">FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication</a></h2>
			<p>November 13, 2017 -- The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.</p>
			
			<center>
				<button href="PLACEHOLDER_LINK" class="radius btn-offset">Read More</button>
			</center>

			<spacer size="16"></spacer>
			<small class="text-muted"><strong>Sent to subscribers of:</strong> Depression, Major Depressive Disorder, Schizophrenia, Bipolar Disorder</small>

		</columns>
	</row>
</container>

{{> footer-social }}